STAT March 4, 2024
Paul Shay

Lack of health data on LGBTQ+ people has real-world consequences. A participant in a 2020 report from the National LGBT Cancer Network said: “There are no guidelines for cancers that are more prevalent among Trans women. I had to fight like hell to have an anoscopy, and sure enough we found [precancerous lesions]!”

That same year, the National Academies of Sciences, Engineering, and Medicine issued a hallmark report on the health and well-being of LGBTQ+ people. It found that social and structural stigma has contributed to lower rates of engagement with the health care system (such as preventative screenings), higher rates of uninsurance and under-insurance, higher rates of many risk factors including smoking and obesity, higher rates of some cancers...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Survey / Study, Trends
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time

Share This Article